Divis Laboratories Sustainability Profile
Divis Laboratories, a leading player in the pharmaceutical and biotechnology sectors, is headquartered in Hyderabad, India. Founded in 1990, the company has established itself as a prominent manufacturer of active pharmaceutical ingredients (APIs) and intermediates, catering to a global clientele. With a strong focus on research and development, Divis Laboratories has achieved significant milestones, including the successful launch of several high-quality products that meet stringent regulatory standards. The company’s core offerings include APIs for various therapeutic areas, particularly in anti-retroviral and anti-cancer medications, which are distinguished by their purity and efficacy. Divis Laboratories is recognised for its robust market position, consistently ranking among the top suppliers in the industry. Its commitment to innovation and sustainability further enhances its reputation as a trusted partner in the pharmaceutical landscape.
DitchCarbon Score
How does Divis Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Divis Laboratories's score of 46 is higher than 64% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Divis Laboratories's reported carbon emissions
In 2024, Divis Laboratories reported total greenhouse gas emissions of approximately 689,218,000 kg CO2e, comprising 363,246,000 kg CO2e from Scope 1 and 325,972,000 kg CO2e from Scope 2. The company has set ambitious climate commitments, aiming to achieve net-zero emissions across its value chain by FY2050. For near-term targets, Divis Laboratories plans to reduce absolute Scope 1 and 2 emissions by 58.8% by FY2034, using FY2024 as the baseline. Additionally, the company aims to cut absolute Scope 3 emissions by 35% within the same timeframe. Long-term goals include a 90% reduction in both Scope 1 and 2 emissions and Scope 3 emissions by FY2050, also from a FY2024 baseline. Divis Laboratories' targets align with the Science Based Targets initiative (SBTi) and are consistent with the reductions necessary to limit global warming to 1.5°C. The company has not disclosed any Scope 3 emissions data as of now, but its commitments reflect a proactive approach to climate action within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 382,670,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 370,742,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Divis Laboratories's Industry?
How Carbon Intensive is Divis Laboratories's Location?
Divis Laboratories's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Divis Laboratories has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Sai Life Sciences
Frequently Asked Questions
Common questions about Divis Laboratories's sustainability data and climate commitments